[HTML][HTML] Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer
MR Stockler, F Hilpert, M Friedlander… - Journal of Clinical …, 2014 - ncbi.nlm.nih.gov
MR Stockler, F Hilpert, M Friedlander, MT King, L Wenzel, CK Lee, F Joly, N de Gregorio…
Journal of Clinical Oncology, 2014•ncbi.nlm.nih.govPatient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating
Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main
Content Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User
Guide Journal List J Clin Oncol PMC4876313 Other Formats PubReader PDF (305K) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles …
Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main
Content Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User
Guide Journal List J Clin Oncol PMC4876313 Other Formats PubReader PDF (305K) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles …
Abstract
Purpose
To determine the effects of bevacizumab on patient-reported outcomes (PROs; secondary end point) in the AURELIA trial.
ncbi.nlm.nih.gov